menu
Cardiac Biomarkers Testing Market: Analysis, Growth Drivers and Trending Factors
Cardiac Biomarkers Testing Market: Analysis, Growth Drivers and Trending Factors
According to the report published by Allied Market Research, the global Cardiac Biomarkers Testing Market was pegged at $9.76 billion in 2020 and is estimated to hit $28.09 billion by 2030, registering a CAGR of 10.9% from 2021 to 2030.

The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.

For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/5284

Rise in prevalence of cardiovascular diseases, emergence of non-invasive biomarkers, and surge in point-of-care (POC) testing drive the growth of the global cardiac biomarkers testing market. On the other hand, stringent government regulations impede the growth to some extent. However, advent of personalized medicines and point-of-care (POCT) testing using cardiac biomarkers are expected to create lucrative opportunities in the industry.

COVID-19 scenario-

Increase in the number of COVID-19 patient with preexisting medical conditions such as cardiovascular diseases has amplified the demand for cardiac biomarker testing across the world.

This trend is most likely to persist for the next few years.

The cardiac biomarkers testing market is analyzed across biomarker type, application, location of testing, and region. Based on biomarker type, the troponins segment accounted for nearly two-fifths of the total market revenue in 2020, and is expected to rule the roost by the end of 2030. The creatine kinase segment, on the other hand, would cite the fastest CAGR of 13.00% during the forecast period.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/5284

Based on application, the myocardial infarction segment contributed to nearly two-fifths of the total market share in 2020, and is projected to lead the trail by 2030. Simultaneously, the congestive heart failure segment would register the fastest CAGR of 12.20% throughout the forecast period.

Based on region, the market across North America held the major share in 2020, garnering nearly two-fifths of the global cardiac biomarker testing market. At the same time, Asia-Pacific would showcase the fastest CAGR of 12.50% from 2021 to 2030. The other regions analyzed through the report Europe and LAMEA.

The leading market players analyzed in the global cardiac biomarkers testing market report include Becton, Dickinson and Company, bioMerieux, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Tosoh Corporation, Danaher Corporation, Abbott Laboratories,  PerkinElmer Inc., and Siemens AG. These market players have adopted different strategies including partnership, expansion, collaboration, joint ventures, and others to reinforce their status in the industry.